PLA2G7 and diabetes mellitus: Based on the stratified observational analysis above, we hypothesised that in the STABILITY trial among those with high Lp-PLA2 activity (Q4, n = 3835), participants with diabetes would benefit more from treatment with an Lp-PLA2 inhibitor than those without diabetes (Fig. 2).